Total amount: € 0,00
HOW TO ORDER
A Journal on Internal Medicine
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6
Panminerva Medica 2014 June;56(2 Suppl 3):1-7
Delphinol® standardized maqui berry extract reduces postprandial blood glucose increase in individuals with impaired glucose regulation by novel mechanism of sodium glucose cotransporter inhibition
Hidalgo J. 1, Flores C. 2, Hidalgo M. A. 1, Perez M. 3, Yañez A. 3, Quiñones L. 4, Caceres D. D. 5, Burgos R. A. 1 ✉
1 Instituto de Farmacología y Morfofisiología, Universidad Austral de Chile, Valdivia, Chile;
2 Centro de Estudios Científicos (CECS), Valdivia, Chile;
3 Instituto de Bioquímica y Microbiología, Universidad Austral de Chile, Valdivia, Chile;
4 CQF, Centro de Investigaciones Farmacológicas y Toxicológicas ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Chile;
5 División de Epidemiología Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile, Santiago de Chile
AIM: The impetus of our study was to investigate the effects of a nutritional supplement Delphinol®, an extract of maqui berries (Aristotelia chilensis) standardised to ≥25% delphinidins and ≥35% total anthocyanins, on postprandial blood glucose and insulin levels and identify the physiologic mechanism involved.
METHODS: Postprandial blood glucose and insulin were investigated in double-blind, placebo-controlled, cross-over fashion in ten volunteers with moderate glucose intolerance. Longer term effects on blood sugar levels were investigated in streptozotocin-diabetic rats over a four months period. Effects of maqui berry delphinidins on sodium-glucose symport were examined in rodent jejenum of the small intestine.
RESULTS: Delphinol® intake prior to rice consumption statistical significantly lowered post prandial blood glucose and insulin as compared to placebo. We identified an inhibition of Na+-dependant glucose transport by delphinidin, the principal polyphenol to which Delphinol® is standardised. In a diabetic rat model the daily oral application of Delphinol® over a period of four months significantly lowered fasting blood glucose levels and reached values indistinguishable from healthy non-diabetic rats.
CONCLUSION: Our results suggest a potential use of Delphinol® for naturally controlling post-prandial blood glucose owed to inhibition of sodium glucose co-transporter in small intestine.